On this Rare Disease Day, let’s talk about the clinical challenges faced by the professionals of the healthcare system. With over 7,000 distinct rare diseases identified globally, the collective burden is immense. In Turkey, it is estimated that 5 to 7 million individuals are currently living with a rare condition, many of whom remain undiagnosed or mismanaged (ERDERA, 2025).

The Clinical Imperative of Genetic Testing

For the modern clinician, genetic testing is no longer a “last resort” but a primary diagnostic pillar.

• Shortening the Diagnostic Odyssey: While the global average for a diagnosis remains 5 years, the shift to Next-Generation Sequencing (NGS) is dramatically altering this timeframe (MDPI Genes, 2025).
• Diagnostic Yield: Early use of Whole Exome Sequencing (WES) or Whole Genome Sequencing (WGS) has been demonstrated to increase diagnostic yield by 30-50% in complex cases, compared to less than 10% for standard phenotypic-led testing (Srivastava et al., 2019).
• Genotype-Phenotype Correlation: Clinicians play an important role in reverse phenotyping. Geneticists use extensive clinical observations to understand Variants of Uncertain Significance (VUS); without exact bedside data, genomic data is incomplete (Medicover Genetics, 2025).

The Turkish Context: A Unique Genetic Landscape

Türkiye’s demographic structure presents specific challenges and opportunities for clinical genetics.

• Consanguinity and Recessive Disorders: With a national consanguineous marriage rate of approximately 24–25%, there is a significantly higher prevalence of autosomal recessive disorders compared to Western Europe (TÜİK, 2023).
• Public Health Success: The integration of the National SMA Screening Program has already demonstrated how clinician-led preventive genetics can reduce disease burden, managing approximately 150–180 new cases per year through early intervention (Turkish Journal of Medical Sciences, 2026).

Key Responsibilities for the Modern Provider

Action	Clinical Significance
Early Referral	Recognizing “red flags” (e.g., developmental delay + dysmorphism). (Srivastava et al., 2019)
Multidisciplinary Leadership	Coordinating care across neurology, cardiology, and metabolic units. (ERDERA, 2025)
VUS Interpretation	Using HPO (Human Phenotype Ontology) terms to clarify genetic findings. (Medicover Genetics, 2025)
Genetic Counseling	Communicating recurrence risks and PGD options to families. (MDPI Genes,2025)

Selecting the Right Genetic Tool: Targeted Panels vs. WES vs. WGS

In the clinical workflow, the choice of test is a balance between “breadth” and “depth.” As genomic technology matures, the “Exome-First” approach is increasingly favored for heterogeneous phenotypes (Srivastava et al., 2019).

Comparative Strategy for Clinicians:

Feature	Targeted Panels	Whole Exome (WES)	Whole Genome (WGS)
Diagnostic Yield	Moderate (30%)	High (35–45%)	Highest (>50%)
Coverage Depth	Very High (>500x)	High (100x)	Moderate (30-50x)
Non-coding Variants	No	No	Yes
CNV Detection	Limited	Moderate	High
Turnaround Time	Fast (2-4 weeks)	Moderate (4-8 weeks)	Variable

According to recent clinical guidelines, the provider’s strategy should follow the “Complexity Escalation” model:

1. Clear Phenotype: If the patient fits a textbook definition (e.g., Noonan Syndrome), start with a Targeted Panel.
2. Heterogeneous Phenotype: If the patient presents with non-specific features (e.g., Global Developmental Delay), bypass panels and move directly to WES with CNV analysis (MDPI Genes, 2025).
3. The “Negative Exome”: If WES is negative but the clinical suspicion remains high, escalate to WGS to investigate intronic variants or complex rearrangements (Srivastava et al., 2019).

Tip: Always consider Trio Analysis (sequencing the patient and both biological parents). This significantly accelerates the filtration of rare variants and increases the diagnostic yield by roughly 15–20% compared to singleton testing (ERDERA, 2025).